Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Equities researchers at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for Bradmer Pharmaceuticals in a report released on Monday, March 31st. HC Wainwright analyst M. Colonnese now forecasts that the company will post earnings of ($0.76) per share for the quarter, down from their prior forecast of $0.47. HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.23 EPS and FY2025 earnings at ($0.76) EPS.
GLX has been the subject of several other research reports. Benchmark upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th.
Bradmer Pharmaceuticals Price Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- The Risks of Owning Bonds
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 5 Reasons the S&P 500 Could Rebound Strongly in 2025
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Best Gold Stocks in 2025… So Far
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
